MAP3K7IP1 (mitogen-activated protein kinase kinase kinase 7 interacting protein 1) Blocking Peptide (the N terminal of protein) (100ug)

Supplier: Aviva Systems Biology Incorporated

0 reviews | Write a Review Pencil

Description
Additional Information

This is a synthetic peptide designed for use in combination with anti-MAP3K7IP1 antibody (Catalogue #: ARP53182_P050) made by Aviva Systems Biology. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications. Please inquire for more details.

Presku:	AAP53182
Size:	100 ug
Weight:	50kDa
Gene:	10454
Format:	Lyophilized powder
Target:	The specific function of the protein remains unknown.The protein encoded by this gene was identified as a regulator of the MAP kinase kinase kinase MAP3K7/TAK1, which is known to mediate various intracellular signaling pathways, such as those induced by TGF beta, interleukin 1, and WNT-1. This protein interacts and thus activates TAK1 kinase. It has been shown that the C-terminal portion of this protein is sufficient for binding and activation of TAK1, while a portion of the N-terminus acts as a dominant-negative inhibitor of TGF beta, suggesting that this protein may function as a mediator between TGF beta receptors and TAK1. This protein can also interact with and activate the mitogen-activated protein kinase 14 (MAPK14/p38alpha), and thus represents an alternative activation pathway, in addition to the MAPKK pathways, which contributes to the biological responses of MAPK14 to various stimuli. Alternatively spliced transcript variants encoding distinct isoforms have been reported.
Alternative names:	3'-Tab1; MGC57664; TAB1